Industry News

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Stryker Completes Acquisition of ZuriMED to Expand Shoulder Care Continuum: Reported by OrthoSpineNews, Stryker acquired privately held ZuriMED to integrate the commercialized FiberLocker® System rotator cuff augmentation technology into its shoulder portfolio, enhancing mechanical repair strength and construct durability.
• Two-Year Survival Analysis Finds Equivalent 83 Percent Survival for Flap-Based Limb Salvage Versus Early Amputation in Geriatric Lower Extremity Trauma: Reported by Healio Orthopedics, an 82-patient multicenter cohort presented at the Orthopaedic Trauma Association Annual Meeting demonstrated an equivalent 83 percent 2-year survival rate between limb salvage and early amputation in patients aged 65 years or older.
• Inaugural 2026 Pain Management Technology Awards Honor Curonix Wireless Freedom PNS System and Allevion Medical Vantage Lumbar Decompression Kit: Reported by Orthopedics This Week, physician review panels recognized Curonix's battery-free peripheral nerve stimulation technology and Allevion Medical's single-use sterile lumbar decompression system for innovation and standard-of-care improvement.
• Medyssey Co, Ltd. Obtains 510(k) Clearance for Odys-SI Screw: Medyssey Co, Ltd. received FDA 510(k) clearance (K262522) for its Odys-SI Screw, indicated for sacroiliac joint fixation.
• Nvision Biomedical Technologies Obtains 510(k) Clearance for Ntegrate Threaded Nail System: Nvision Biomedical Technologies secured FDA 510(k) clearance (K261961) for its Ntegrate Threaded Nail System, indicated for bone fracture and osteotomy fixation.

DAILY ANNOUNCEMENTS BY CATEGORY

Corporate, M&A & Regulatory

Stryker: Stryker Completes Acquisition of ZuriMED to Expand Shoulder Care Portfolio With FiberLocker Rotator Cuff Augmentation Technology

• Summary: Stryker completed the acquisition of ZuriMED, a privately held developer of the commercialized FiberLocker® System. The technology is designed to increase the biomechanical strength of surgical rotator cuff repairs, expanding Stryker's shoulder care continuum with differentiated soft-tissue augmentation expertise. Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, stated that ZuriMED complements Stryker's growing shoulder care capabilities to advance FiberLocker® technology and deliver clinical value across its global reach of more than 150 million patients annually.
• Key Details:
  • Device/System Name: FiberLocker® System
  • Status: Acquisition Completed / Commercial Rotator Cuff Augmentation Technology
  • Clinical Significance: Enhances rotator cuff repair durability by providing mechanical augmentation to increase construct failure load and reduce structural re-tear rates, addressing an important unmet need in primary and revision rotator cuff surgery.
• Original Source: OrthoSpineNews

Trauma & Extremities

University of Maryland / R Adams Cowley Shock Trauma Center: Two-Year Survival Analysis Finds Equivalent 83 Percent Survival for Flap-Based Limb Salvage Versus Early Amputation in Severe Geriatric Lower Extremity Trauma

• Summary: A retrospective cohort study led by Dr. Christopher G. Langhammer, MD, PhD, microvascular trauma specialist at the University of Maryland School of Medicine and R Adams Cowley Shock Trauma Center, presented at the Orthopaedic Trauma Association Annual Meeting (OTA Paper 36) evaluated 82 patients aged 65 years or older presenting with limb-threatening lower extremity injuries. Investigators compared 2-year survival following early amputation (18 patients) versus flap-based limb salvage reconstruction (64 patients), demonstrating an equivalent 83 percent 2-year survival rate in both cohorts over 15 years of experience. Early amputation patients achieved final surgical care and discharge by 3 months, whereas nearly 25 percent of limb salvage patients experienced care trajectories exceeding 1 year and 25 percent required secondary amputation; Langhammer highlighted that with 1 in 5 patients dying within 2 years regardless of pathway, decision-making remains highly preference-sensitive.
• Key Details:
  • Device/System Name: Flap-Based Limb Salvage and Microvascular Reconstruction Cohort (OTA Paper 36)
  • Status: Multicenter Cohort Study Presented (Orthopaedic Trauma Association Annual Meeting)
  • Clinical Significance: Provides crucial prognostic data for complex geriatric trauma decision-making, demonstrating that attempting flap-based limb salvage does not compromise two-year survival compared to early amputation, though surgeons and families must weigh a one-year arc of care and a 25 percent secondary amputation risk against rapid rehabilitation following early amputation.
• Original Source: Healio Orthopedics

Spine & Orthobiologics

Curonix / Allevion Medical: Orthopedics This Week Inaugural 2026 Pain Management Technology Awards Honor Curonix Wireless Freedom PNS System and Allevion Medical Vantage Lumbar Decompression Kit

• Summary: Orthopedics This Week announced the recipients of its inaugural Pain Management Technology Awards, judged by orthopedic surgeon panels across 6 clinical criteria including innovation, long-term significance, and standard-of-care improvement. First place was awarded to Curonix for its Freedom Peripheral Nerve Stimulator (PNS) System, an implantable battery-free neurostimulation system for refractory postsurgical knee and shoulder pain powered wirelessly by an external transmitter through up to 6 cm of tissue. Second place was awarded to Allevion Medical for its Vantage Lumbar Decompression Kit, a sterile single-use disposable surgical kit featuring an integrated neural protection guard, 4-position drill guide, and disposable LED illumination cleared under the 510(k) pathway in 2026 to eliminate instrument reprocessing bottlenecks in hospitals and ASCs.
• Key Details:
  • Device/System Name: Freedom Peripheral Nerve Stimulator (PNS) System & Vantage Lumbar Decompression Kit
  • Status: Inaugural Pain Management Technology Awards Announced (Orthopedics This Week)
  • Clinical Significance: Addresses refractory chronic postsurgical pain following total joint arthroplasty with battery-free peripheral neuromodulation, while providing sterile disposable instrumentation to streamline outpatient lumbar decompression workflows and eliminate instrument reprocessing bottlenecks.
• Original Source: Orthopedics This Week

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES: ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2 to 4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.